You are here: Industry Insights > Biosciences

News List

Are the Fourth Generation EGFR Inhibitors the Next Wealth Creation Myth? PharmaSources/Yefenghong
April 18, 2022
Junshi Biosciences WJ13404 Has Been Submitted for Clinical Application
Cytek Biosciences Achieves ISO 9001:2015 certification contractpharma
May 20, 2019
Certification applies to Cytek’s headquarters and manufacturing operations in Fremont, CA, for the design, build and support of flow cytometers and accessories.
Bayer invests in Khloris’ anti-cancer vaccines programme pharmaceutical-technology
April 23, 2019
Bayer invests in Khloris’ anti-cancer vaccines programme.
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics en-cphi.cn
December 10, 2018
WuXi Biologics announces a strategic collaboration with Brii Biosciences.
Two Senior Business Development Executives Join Life Biosciences americanpharmaceuticalreview
November 19, 2018
Sree Kant and Michael Ringel, JD, PhD, have been appointed to senior business development positions, according to an ann
Avance Completes Successful FDA Inspection contractpharma
November 01, 2018
Avance Completes Successful FDA Inspection
Quadrant Biosciences, Autism Speaks to Study Minocycline as Autism Treatment americanpharmaceuticalreview
October 30, 2018
Quadrant Biosciences, Autism Speaks to Study Minocycline as Autism Treatment
Nutriband to Acquire Carmel Biosciences americanpharmaceuticalreview
September 27, 2018
Nutriband has signed the definitive acquisition agreement to acquire Carmel Biosciences. The acquisition is expected to be valued at approximately $2,700,000 and will be paid in company stock in the amount of 350,000 restricted common shares.
Genocea Biosciences Announces Pricing of $55M Concurrent Public Offerings biospace
January 18, 2018
Genocea Biosciences announced today that its simultaneous public offering includes (i) 53,365,000 ordinary shares and the accompanying Class A warrants
Canopy Biosciences Announces Distribution Agreement with Cosmo Bio biospectrumasia
June 26, 2017
The genetic engineering market continues to grow at a rapid pace in Japan and Cosmo Bio anticipates that the TUNR technology will become a key factor in gene editing.